TAIPEI, Taiwan (AP) ? Taiwan is asking Apple Inc. to blur a map image of its new $1.4 billion early warning radar station that can detect aircraft and missiles coming from as far as western China.
Defense Ministry spokesman David Lo said Tuesday that Apple should follow its rival Google in using only low-resolution satellite pictures to show sensitive facilities. He acknowledged the military should also try to camouflage them.
The 10-story high radar installation built with U.S. technology is expected to go online later this year. It's near the Hsinchu Air Base in northern Taiwan.
The satellite picture that can be viewed with iPhones is believed to have been taken a year ago.
Local media say the radar installation can monitor targets, determine their speeds and fire missiles to intercept them.
Digital media is premised on innovation. It is the lifeblood of agencies and can be a calling card for brands. But it is, also, often enough, an exercise in public relations. Many publications, Digiday included, are eager to be the ?first? to something or other. The result is many ?innovations? are really closer to PR stunts that are measured not on business results or even R&D but on ?earned media.? There are even times, shockingly, that these things are done by agencies in the hopes of winning awards.
The downside of that is what?s been termed ?bright, shiny object? syndrome, where an article on Mashable or Fast Company sends brand managers scrambling to ?get me one of those.? There?s a reason so many brands rushed into Second Life, after all. Aaron Shapiro, CEO of Huge, said during Advertising Week that many clients are so distracted by the New New Thing that they neglect the basics that can actually change their businesses.
With this in mind, Digiday is starting a series that will examine the relative merits of a new talked-about effort to determine which it is: genuine innovation or PR exercise. We?ll list the case for each and invite you to weigh in on the comments, on Twitter, on Facebook or through good old-fashioned email. Please also send along nominations for future installments of ?Innovation or PR??
This week we look at the Lexus print campaign with Sports Illustrated that lets users bring a print ad to life with their iPads.
Lexus and agency TeamOne have developed technology called CinePrint that has allowed what it bills a ?print-digital ad mash-up? in the new issue of Sports Illustrated. Here?s what happens: Readers of Sports Illustrated take the print ad and place it over their iPad screen when it?s showing the iPad edition of Sports Illustrated or a specific page of the Lexus website. The ad then ?comes to life? with sight, sound and motion by playing images that shine through the page. It makes it appear as though the Lexus in the print ad is spinning its wheels and actually driving.
The Innovation Case: Static media has to become more interactive. There?s no doubt a wow factor in the idea that a boring old magazine ad can come to life. This is, in some ways, a form of augmented reality, which was quite popular with creative agencies for a while.
The PR Case: Who in their right mind is going to read a magazine, then bring it over to their iPads to do this? There?s a reason AR never really caught on with consumers as much as advertisers. It?s too much work for too little payoff. The campaign?s slick overview video is perfect for blogs and publications. Mashable wrote about the effort this week and wondered if it is ?the future of print advertising.?
Duke Medicine news -- Anti-cancer drug fights immune reaction in some infants with Pompe diseasePublic release date: 11-Oct-2012 [ | E-mail | Share ]
Contact: Sarah Avery sarah.avery@duke.edu 919-660-1306 Duke University Medical Center
DURHAM, N.C. Adding a third anti-cancer agent to a current drug cocktail appears to have contributed to dramatic improvement in three infants with the most severe form of Pompe disease -- a rare, often-fatal genetic disorder characterized by low or no production of an enzyme crucial to survival.
Duke researchers previously pioneered the development of the first effective treatment for Pompe disease via enzyme replacement therapy (ERT). ERT relies on a manufactured enzyme/protein to act as a substitute for the enzyme known to be lacking in patients with a particular disease. In Pompe disease, ERT has been found to reduce heart and muscle damage caused by the absence of the enzyme.
In the new study, appearing online in the Oct. 11, 2012, edition of the journal Genetics in Medicine, the Duke team added a new step to the therapeutic regimen to address complications suffered by a subset of infants with Pompe disease who are treated with ERT.
Some infants with Pompe disease who have certain combinations of genetic mutations develop a severe immune response to ERT. Very high levels of antibodies become directed against the enzyme and greatly reduce its therapeutic effect, leading to rapid clinical decline and death.
In a January 2012 publication in Genetics in Medicine, the researchers reported success in preventing the immune rejection in Pompe infants who were just beginning ERT. They treated them with a drug cocktail that included low doses of the cancer chemotherapy drugs rituximab and methotrexate, plus the immune booster gammaglobulin to prevent the immune response to the ERT.
The three cases described in the new paper had already received the ERT for a prolonged period of time and, despite initial improvements, declined rapidly as their bodies developed high levels of antibodies that blocked the effect of the enzyme replacement. In these youngsters, plasma cells, which are the ultimate source of antibody production, were left untouched by the immune-suppressing drug cocktails.
"These plasma cells form rapidly after exposure to ERT, and some of them are what we call long-lived plasma cells that survive for years, continuing to spew out antibodies," explained senior author Priya Kishnani, M.D., professor of Pediatrics and Medical Genetics at Duke.
After testing their ideas in mouse models of Pompe disease, the Duke researchers added a proteasome inhibitor called bortezomib to the regimen. Bortezomib, which is FDA-approved to treat multiple myeloma and mantle cell lymphoma, targets the plasma cells and inhibits the production of antibodies, reversing the established immune response.
In all three cases the antibodies decreased rapidly. Just as rapidly, each of the babies' conditions dramatically improved and the babies have continued to do well.
"I'm absolutely delighted, because to me this has become life-saving for these fragile babies," Kishnani said. "This is what I truly think is translational research, where you learn about a problem in patients, address it in an animal model and take it back into the patients to make a difference."
"We were encouraged with the positive results from preclinical studies using bortezomib. We quickly developed a clinical protocol using bortezomib for infantile Pompe patients that had failed conventional treatment. It was truly a satisfying experience," said first author Suhrad Banugaria, MBBS, postdoctoral associate in Pediatrics Medical Genetics at Duke.
Next, the group is working to develop treatments that more specifically target antigens eliciting immune responses to ERT. Kishnani and colleagues hope that such a targeted approach might minimize the impact on the immune system generally.
Kishnani said the insights her team has gained treating Pompe disease could be applied to other diseases in which an immune response has also been shown to reduce the impact of enzyme replacement therapy.
"We're already getting calls for other conditions such as mucopolysaccharidosis and Fabry disease, where physicians are facing the same issues: patients who have developed a significant antibody response and are not doing as well, or have started to show a clinical decline," Kishnani said.
###
In addition to Kishnani and Banugaria, authors include Sean N. Prater, Duke Department of Pediatrics; Judeth K. McGann, Jonathan D. Feldman, and Jesse A. Tannenbaum of Kaiser Permanente, Santa Clara, Cal.; Carrie Bailey and David Viskochil of the University of Utah; Renuka Gera and Robert L. Conway of Michigan State University; Joyce A. Kobori of Kaiser Permanente, San Jose, Cal.; and Amy S. Rosenberg of the U.S. Food and Drug Administration, Bethesda, Md.
Kishnani reports receiving research support, honoraria and consulting fees from Genzyme, which markets an ERT for Pompe disease. Duke University and the inventors of the method of treatment and precursors of the cell lines used to generate the enzyme (rhGAA) used commercially have received royalties pursuant to the university's policy on inventions, patents, and technology transfer. This potential conflict has been resolved through monetization. Full dislosures of conflicts are listed in the manuscript.
Click on link for a conceptual diagram of the immune response: http://www.dukehealth.org/pompe-disease-graphic
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Duke Medicine news -- Anti-cancer drug fights immune reaction in some infants with Pompe diseasePublic release date: 11-Oct-2012 [ | E-mail | Share ]
Contact: Sarah Avery sarah.avery@duke.edu 919-660-1306 Duke University Medical Center
DURHAM, N.C. Adding a third anti-cancer agent to a current drug cocktail appears to have contributed to dramatic improvement in three infants with the most severe form of Pompe disease -- a rare, often-fatal genetic disorder characterized by low or no production of an enzyme crucial to survival.
Duke researchers previously pioneered the development of the first effective treatment for Pompe disease via enzyme replacement therapy (ERT). ERT relies on a manufactured enzyme/protein to act as a substitute for the enzyme known to be lacking in patients with a particular disease. In Pompe disease, ERT has been found to reduce heart and muscle damage caused by the absence of the enzyme.
In the new study, appearing online in the Oct. 11, 2012, edition of the journal Genetics in Medicine, the Duke team added a new step to the therapeutic regimen to address complications suffered by a subset of infants with Pompe disease who are treated with ERT.
Some infants with Pompe disease who have certain combinations of genetic mutations develop a severe immune response to ERT. Very high levels of antibodies become directed against the enzyme and greatly reduce its therapeutic effect, leading to rapid clinical decline and death.
In a January 2012 publication in Genetics in Medicine, the researchers reported success in preventing the immune rejection in Pompe infants who were just beginning ERT. They treated them with a drug cocktail that included low doses of the cancer chemotherapy drugs rituximab and methotrexate, plus the immune booster gammaglobulin to prevent the immune response to the ERT.
The three cases described in the new paper had already received the ERT for a prolonged period of time and, despite initial improvements, declined rapidly as their bodies developed high levels of antibodies that blocked the effect of the enzyme replacement. In these youngsters, plasma cells, which are the ultimate source of antibody production, were left untouched by the immune-suppressing drug cocktails.
"These plasma cells form rapidly after exposure to ERT, and some of them are what we call long-lived plasma cells that survive for years, continuing to spew out antibodies," explained senior author Priya Kishnani, M.D., professor of Pediatrics and Medical Genetics at Duke.
After testing their ideas in mouse models of Pompe disease, the Duke researchers added a proteasome inhibitor called bortezomib to the regimen. Bortezomib, which is FDA-approved to treat multiple myeloma and mantle cell lymphoma, targets the plasma cells and inhibits the production of antibodies, reversing the established immune response.
In all three cases the antibodies decreased rapidly. Just as rapidly, each of the babies' conditions dramatically improved and the babies have continued to do well.
"I'm absolutely delighted, because to me this has become life-saving for these fragile babies," Kishnani said. "This is what I truly think is translational research, where you learn about a problem in patients, address it in an animal model and take it back into the patients to make a difference."
"We were encouraged with the positive results from preclinical studies using bortezomib. We quickly developed a clinical protocol using bortezomib for infantile Pompe patients that had failed conventional treatment. It was truly a satisfying experience," said first author Suhrad Banugaria, MBBS, postdoctoral associate in Pediatrics Medical Genetics at Duke.
Next, the group is working to develop treatments that more specifically target antigens eliciting immune responses to ERT. Kishnani and colleagues hope that such a targeted approach might minimize the impact on the immune system generally.
Kishnani said the insights her team has gained treating Pompe disease could be applied to other diseases in which an immune response has also been shown to reduce the impact of enzyme replacement therapy.
"We're already getting calls for other conditions such as mucopolysaccharidosis and Fabry disease, where physicians are facing the same issues: patients who have developed a significant antibody response and are not doing as well, or have started to show a clinical decline," Kishnani said.
###
In addition to Kishnani and Banugaria, authors include Sean N. Prater, Duke Department of Pediatrics; Judeth K. McGann, Jonathan D. Feldman, and Jesse A. Tannenbaum of Kaiser Permanente, Santa Clara, Cal.; Carrie Bailey and David Viskochil of the University of Utah; Renuka Gera and Robert L. Conway of Michigan State University; Joyce A. Kobori of Kaiser Permanente, San Jose, Cal.; and Amy S. Rosenberg of the U.S. Food and Drug Administration, Bethesda, Md.
Kishnani reports receiving research support, honoraria and consulting fees from Genzyme, which markets an ERT for Pompe disease. Duke University and the inventors of the method of treatment and precursors of the cell lines used to generate the enzyme (rhGAA) used commercially have received royalties pursuant to the university's policy on inventions, patents, and technology transfer. This potential conflict has been resolved through monetization. Full dislosures of conflicts are listed in the manuscript.
Click on link for a conceptual diagram of the immune response: http://www.dukehealth.org/pompe-disease-graphic
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
OAKLAND -- Grant Balfour didn't even pitch in Game 4, yet he still had a huge impact on the game. Facing elimination and down two runs in the ninth inning, the A's season looked to be on life support. That's when the ultra-intense closer fired up the A's dugout with a passionate speech. Four hits later the A's were on the field celebrating their 15th walk-off win of the season and seventh in A's postseason history.
During the ninth inning Balfour was told to go to the bullpen to warm up. He eventually did but not before giving the A's a pep talk.
"It was no disrespect to anyone but I said 'We are going to rock this guy's world tonight. We're going to walk it off in A's fashion, that's what we do," Balfour recalled. "Believe it. Every one of you put your mind to it and believe it, and see yourselves running onto that field with that walk-off victory," he told his teammates.
"See it and believe it," he repeated.
They believed alright. As the sell-out crowd of 36,385 wondered if the A's had any magic left in them this season, the A's answered their question. Josh Reddick hit a leadoff single. Josh Donaldson doubled off the wall in left field -- just missing a game-tying home run. Seth Smith smacked a game-tying two-run double to right field. Coco Crisp then connected for the knockout blow, a walk-off RBI single to right field to give the A's a 4-3 win.
"I believe in the mind as a powerful thing," Balfour said. "It was unbelievable. If you really want something bad enough and you've got every guy in the dugout that wants it and he's thinking the same thing and believes it, it just goes to show."
Maybe what the A's are accomplishing isn't magic. They are just insanely determined, and a little ignorant.
[RATTO: A's are more than just magic]
"We've heard a lot of people say we aren't smart enough to know when to lose a game like most people do," Josh Reddick said. "We've been battling to the 27th out all year and we are not going to stop now."
Reddick said he took the brunt of Balfour's rage in the dugout before he led off the ninth inning with a single. Maybe he needed the abuse. Reddick struck out in his first two plate appearances running his strikeout total in this series up to eight -- the most by any A's hitter in a single playoff series. ?
"He was hitting me and hugging me and all that crazy stuff he usually does," Reddick said. "He kept telling us 'We aren't going to lose this game. We aren't going to lose this game.' We firmly believe in that."
"A two-run deficit isn't enough to hold us right now," Reddick added.
The A's often say they don't quit until the final out. It's hard to doubt them at this point. This game was all Tigers until the sixth inning. Detroit's starting pitcher Max Scherzer struck out eight and had the A's hitters baffled. When Oakland finally got to him they made a seemingly crippling mistake.
Stephen Drew doubled home Crisp in the sixth with no outs but got thrown out by several steps as he tried to make it to third. A's third base coach Mike Gallego didn't put on the stop sign. At that point it was a 2-1 game and Drew would have been the tying runner with Yoenis Cespedes due up.
"It wasn't a good call, it wasn't a good play," Gallego said. "I felt that I couldn't have stopped him either. If I would have stopped him I would have gotten him hung out to dry in the middle of the base paths."
It seems there's always a moment like that that unravels the A's in the playoffs. The moment where Jeremy Giambi doesn't slide in 2001, or when Eric Byrnes doesn't touch the plate in 2003. It looked like Gallego would be the scapegoat for the A's getting eliminated. Things looked even more bleak when the Tigers added a run in the eighth off reliever Sean Doolittle.
The 2012 A's aren't phased by these things. In the end, the play and the Tigers' insurance run didn't mean a thing as the A's got the last laugh in the bottom of the ninth.
"It's huge, it's playoff baseball," Donaldson said. "We're down to our last three outs right there. For me to come through right there the amount of emotion going through me right there was just uncontainable at the time."
Like Balfour, Donaldson was so fired up after the game that he didn't flinch when asked if he was going to sleep tonight.
"I'm not," he said.
Crisp might have sweet dreams. He was still sticky from the postgame pie and Gatorade when he addressed the media. A veteran in more ways than one, at this point he is used to taking the brunt of the A's celebratory dessert. He is responsible for four of the A's 15 walk-offs.
"There's certainly guys we feel good about," Melvin said. "But I don't think there's anybody we feel better about in that situation than Coco."
The A's live to fight another day? again. After dropping the first two games of the series in Detroit they will play a win-or-go-home fifth game here at the Coliseum on Thursday night. One thing is clear, they aren't ready to go home. Not if Balfour has anything to say about it.
"I want it so bad," Balfour said. "I know everyone in here wants it so bad. I didn't want to go home tonight. No chance."
The A's have now won back-to-back elimination games for the second time in Athletics history. The last time they did it was in the 1973 World Series when they ended up beating the Mets after trailing 3-2. If the A's can continue their improbable run they will have to defeat reigning American League MVP and Cy Young award-winner Justin Verlander. He is 3-0 against the A's this season. Jarrod Parker will get the ball for the A's.
The main goal of the website is to create moments of enjoyment, entertainment, joy and happiness and to lighten human burdens by presenting the tonic for mind and body, i.e.humor.
create moments of enjoyment, entertainment, joy and happiness and to lighten human burdens by presenting the tonic for mind and body, i.e.humor. humor in all its forms and manifestations. We offer clean humor, joke and satire for laughter, smile and relief from stress, tension, depression, anxiety and resentment.
Read full story on http://www.humorworkcenter.com ?
International Monetary Fund (IFM) chief Christine Lagarde reacts during a news conference at the IMF and World Bank's annual general assembly in Tokyo, Thursday, Oct. 11, 2012. (AP Photo/Itsuo Inouye)
International Monetary Fund (IFM) chief Christine Lagarde reacts during a news conference at the IMF and World Bank's annual general assembly in Tokyo, Thursday, Oct. 11, 2012. (AP Photo/Itsuo Inouye)
International Monetary Fund (IFM) chief Christine Lagarde speaks during a news conference at the IMF and World Bank's annual general assembly in Tokyo, Thursday, Oct. 11, 2012. (AP Photo/Itsuo Inouye)
TOKYO (AP) ? The head of the International Monetary Fund on Thursday called for urgent action to tackle Europe's debt problems and an approaching fiscal crisis in the U.S., warning that the struggling world economy is already falling short of even pessimistic expectations.
IMF chief Christine Lagarde, speaking to reporters as the IMF and World Bank began their annual meetings in Tokyo, praised recent steps taken by the European Central Bank and European governments, but said "more needs to happen, and faster."
Later in the day, finance ministers and central bankers from the Group of Seven richest nations will hold an informal gathering where they will likely discuss steps to address Europe's debt crisis, weaker growth in Asia and an impending budget impasse in the U.S.
The IMF has scaled back its global growth forecast for 2012 to 3.3 percent from 3.5 percent, and has warned that even its dimmer outlook might prove too optimistic if Europe and the United States fail to resolve their crises.
"We are not expecting a very, very strong recovery. The recovery continues, but it continues more slowly than we had expected earlier this year," said Lagarde. The slowdown is "having a ripple effect on emerging markets, and in particular in Asia."
Lagarde also said two senior Chinese finance officials who cancelled their trip to Tokyo amid a territorial dispute with host Japan will "lose out" by not attending. "Our concern is that they will be missing a great meeting," she said. "We have a lot of substantive issues to discuss."
Diplomatic tensions have flared between the two Asian giants over a cluster of tiny islands in the East China Sea controlled by Japan but also claimed by China. In an apparent sign of Beijing's anger over the issue, People's Bank of China Gov. Zhou Xiaochuan, who was scheduled to give the event's closing speech on Sunday, will not be attending. His deputy will represent him in the meeting and deliver the speech.
Lagarde stressed that economies in Asia are critical to global growth, and hoped that disputes between countries in the region can be resolved for the good of economic cooperation in Asia and the rest of the world.
"We hope that differences, however longstanding, can be resolved harmoniously and expeditiously so that from an economic point of view cooperation can continue ... since we are all very closely interconnected," she said.
Japanese auto sales in China plunged last month, and tens of thousands of Chinese tourists have cancelled trips to Japan, which is depending on China as a source of growth amid the global slowdown. The dispute is also an economic negative for China. Before tensions escalated, China's economy was already slowing and grew at its slowest rate in three years in the second quarter.
Lagarde praised the recent steps to shore up Europe's financial system, which has been burdened by high government debt and weak banks in countries such as Greece and Spain, but stressed that more needs to be done.
The ECB has decided to buy unlimited amounts of government bonds to help lower borrowing costs but countries that want to benefit from that measure need to apply to other euro nations for a bailout first.
European governments have also taken steps to reduce budget deficits. A proposal to design a European banking supervision system, however, has run into obstacles, with Germany wanting more time to finalize details before making the ECB the supervisor of banks.
Greece, Ireland and Portugal have already received bailouts from the IMF, European Central Bank and European Union. Spain has worried investors by declining so far to ask for financial aid from the 17 country grouping that uses the euro currency.
"Action has already occurred," Lagarde said. "But more needs to happen and faster.
She also said the U.S. faces major risks in the so-called "fiscal cliff" in 2013, when tax increases and deep spending cuts will take effect unless Congress breaks a budget impasse.
The IMF has urged the U.S. to raise the ceiling on the level of debt the government can issue, which is capped by law. In August 2011, a battle between the Obama administration and Congress over raising the limit wasn't resolved until the U.S. almost defaulted on its debt.
"Here, too, decisive action is expected," she said.
World Bank President Jim Yong Kim, meanwhile, told reporters that while the annual meeting's main preoccupation is staving off recession among the world's most advanced economies, it also needs to lay the foundation for helping developing nations escape poverty.
China and other emerging economies may not need the bank's financing but they still can benefit from its expertise, Kim said.
Kim has announced his mission is to "bend the arc of history" in ending poverty. That requires effective ways to combat and mitigate climate change, help keep food prices under control and take risks of natural disasters into account in national planning, he says.
"Everyone is vulnerable during times of uncertainty, but especially the poor," he said.
The volatile situation in countries engulfed in the "Arab Spring" protests demonstrates vividly the need for growth that generates jobs, especially for the young and for women. That is all the more crucial in "fragile" states affected by conflict, where disaffected or idle young workers may just pick up arms if they have no better options, Kim said.
"If you have economic growth that is not inclusive you are building instability into your system," he said.
___
AP Business Writer Elaine Kurtenbach contributed to this report.
I feel like the more I concentrate on myself (as in working on myself, my issues, etc.) the less happy I am. What?s the deal with ?self improvement??
Your question reminds a time when an acquaintance told me that she finds bliss when someone witnesses how she is a screw-up. When I asked her to say more, she talked about how she is more likely to pay attention, take the screw up seriously, and then work to ?redeem herself? when someone witnesses it. Yes, there are spiritual undertones to what she is saying. Go with it. It?s true.Failing in isolation fosters denial.?
And when you?re in denial?which is really a euphamism for lying to yourself?you impede your progress. That?s the amazing thing about truth: it marches on whether you join it or not. But the sooner you join it, the sooner you?ll get to living the amazing life that?s been there all along waiting for you.
Unfortunately, sometimes we are so in love with what we want, we get stuck, unless somebody shines a light on our blind spot. At the very least, having someone call you on your truth will give you the opportunity to fail differently. And failing differently is what this self-improvement process is all about.
And this gets to the heart of your question: When you?re working on yourself along with someone else, it?s much easier to avoid that ?less happy? feeling you?re having. It?s been proven that a man catches more fish when he fishes along side another than when he fishes alone. It?s also been proven that what makes people happy is having bonds with others?human connection?so?partnering with another makes you happy because steppin? up your game is exhilarating! Your expertise is witnessed. Failures are noted. It?s easier to laugh at your mistakes. You bounce back faster. You have a greater chance of seeing your mission through to the end.
Since we?re talking happiness, it bears mentioning here that we get the highest dopamine rush just before the mission is accomplished. Once you nail it, the rush is over and it?s ?come down from the mountain? time. You still get to enjoy the pleasure of the bond, but the high doesn?t sustain.
Because the high is short-lived, some people opt instead for going for Mission Meaningfulness, which to me is just Happiness 2.0, and something I?m all about. Basically this involves subscribing to the common theme of every mainstream belief system: focus on any life form 10 times more than?yourself if you want to find meaning in life. Do not listen to Ayn Rand if you want to be a happy man. Look around and you?ll find that those who live by this principle have a greater sense that their life is meaningful and infinite.They are not stuck in a rut complaining about being unhappy. The ?I/me? almost seems irrelevant when we?re busy helping a local school plant a garden or volunteering at a food bank. When you?re living Happiness 2.0, it?s bigger than you, so procrastinating, bailing, and denial are not options.
But be careful with this Happiness 2.0 mission and avoid focusing on those who don?t seek your help. I can?t emphasize enough that one needs to acknowledge boundaries and avoid rescuing where it isn?t wanted. Meaningful to all is essential.
We need each other to be happy. And that?s why my final piece of advice to you is: Never improve alone.
If you want a partner to witness your happiness mission, I?d love for you to get in touch.
![[ Back to EurekAlert! ]](http://www.eurekalert.org/images/back2e.gif){kind=small}
Public release date: 11-Oct-2012
Share ] 
